Cargando…

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS

BACKGROUND: Patients are often treated with high doses or combinations of antipsychotics. High doses are associated with more severe side effects and reduction of motivation and drive, which may hamper recovery. Nevertheless, dose-reduction (DR) or discontinuation of antipsychotic medication in chro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bogers, Jan, Hambarian, George, Vermeulen, Jentien, de Haan, Lieuwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234085/ http://dx.doi.org/10.1093/schbul/sbaa029.806

Ejemplares similares

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
por: Bogers, J., et al.
Publicado: (2021)

T38. POSTER PRESENTATION: HAMLETT: HANDLING ANTIPSYCHOTIC MEDICATION, A LONGTERM EVALUATION OF TARGETED TREATMENT A PRAGMATIC SINGLE-BLIND RANDOMISED CONTROLLED TRIAL OF CONTINUATION VERSUS DISCONTINUATION OF PSYCHOTIC MEDICATION
por: van‘t Hag, Erna
Publicado: (2020)

T215. THE ANTIPSYCHOTIC ACTION OF HALOPERIDOL IN PSYCHOTIC-LIKE RATS REQUIRES PRESYNAPTIC VESICULAR ACCUMULATION
por: Müller, Christian, et al.
Publicado: (2020)

T8. ANTIPSYCHOTIC TREATMENT AND EYE MOVEMENT ABNORMALITIES IN SCHIZOPHRENIA
por: Takahashi, Junichi, et al.
Publicado: (2020)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS
por: Susanne Neumeier, Maria, et al.
Publicado: (2020)

T23. ANTIPSYCHOTIC EXPOSURE AND STRIATAL FUNCTIONAL CONNECTIVITY IN PSYCHOSIS RELAPSE: A HYPOTHESIS GENERATING STUDY
por: Rubio, Jose, et al.
Publicado: (2020)

T167. QUALITATIVE DIFFERENCES IN LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS AMONG SCHIZOPHRENIA PATIENTS
por: Karakasi, Valeria, et al.
Publicado: (2020)

T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
por: Ju Lee, Bong, et al.
Publicado: (2020)

T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Abbs, Brandon, et al.
Publicado: (2020)

T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES
por: Mongan, David, et al.
Publicado: (2020)

T174. ANTIPSYCHOTICS AND THE MICROBIOME
por: Chen, Anderson, et al.
Publicado: (2020)

T79. BALANCING EFFECTS WITH SIDE-EFFECTS: EXAMINING COMPARATIVE METABOLIC CONSEQUENCES OF 18 ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA USING NETWORK META-ANALYSIS
por: Pillinger, Toby, et al.
Publicado: (2020)

T214. ANTIPSYCHOTIC TREATMENT PATTERNS AND EFFECTS DURING THE EARLY YEARS AMONG 316 NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA FROM THE OPUS TRIAL
por: Albert, Nikolai, et al.
Publicado: (2020)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

T140. PERSONALITY AND NEUROCOGNITIVE CORRELATES OF PSYCHOTIC-LIKE EXPERIENCES
por: Blain, Scott, et al.
Publicado: (2020)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

T206. ANTIPSYCHOTIC EFFECTIVENESS FOCUSING ON INSIGHT
por: Stabell, Lena, et al.
Publicado: (2020)

T43. PREDNISOLONE VERSUS PLACEBO AS AUGMENTATION THERAPY IN PSYCHOTIC DISORDERS
por: Lyliana, Nasib, et al.
Publicado: (2020)

T220. IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC SIDE EFFECTS ON FUNCTIONING FROM A SCHIZOPHRENIA PATIENT PERSPECTIVE: GLOBAL PATIENT CENTERED SURVEY INCLUDING PATIENTS FROM ITALY
por: Weiss, Catherine, et al.
Publicado: (2020)

T112. PTSD AS A MEDIATOR OF THE RELATIONSHIP BETWEEN TRAUMA AND PSYCHOTIC EXPERIENCES
por: Strelchuk, Daniela, et al.
Publicado: (2020)

T123. RISK FACTORS FOR PSYCHOTIC DISORDERS WITHIN MIGRANT GROUPS IN CANADA
por: Anderson, Kelly, et al.
Publicado: (2020)

T56. RISKY DECISION-MAKING IMPAIRMENT IN EARLY-STAGE PSYCHOTIC BIPOLAR DISORDER
por: Chung Man Ng, Mary, et al.
Publicado: (2020)

T104. PSYCHOTIC-LIKE EXPERIENCES AND PROBLEMATIC GAMING BEHAVIOR IN ONLINE GAME FORUMS
por: Santesteban-Echarri, Olga, et al.
Publicado: (2020)

T202. THE EFFECT OF ANTIPSYCHOTIC DRUGS ON MEMBRANE FUSION: AN IN VITRO STUDY
por: Adrien, Vladimir, et al.
Publicado: (2020)

T87. CHANGING RATES OF PAST-YEAR CANNABIS USE BY PEOPLE WITH A PSYCHOTIC DISORDER
por: Waterreus, Anna, et al.
Publicado: (2020)

T124. ATOPY INCREASES RISK OF PSYCHOTIC EXPERIENCES: A LARGE POPULATION-BASED STUDY
Publicado: (2020)

T199. 7% WEIGHT CHANGE ASSOCIATED WITH ANTIPSYCHOTICS: A META-ANALYSIS
por: Crins, Joost, et al.
Publicado: (2020)

T82. THE IMPACT OF SMOKING ON LIFE EXPECTANCY IN PSYCHOTIC DISORDERS, AN ELECTRONIC CASE REGISTER COHORT STUDY
por: Chesney, Edward, et al.
Publicado: (2020)

T195. PSYCHOTIC DISORDERS IN PATIENTS WHO USE SYNTHETIC CANNABINOIDS: CLINICAL CHARACTERISTICS AND PATIENT PROFILE
por: Skriabin, Valentin, et al.
Publicado: (2020)

T101. ABERRANT SALIENCE PREDICTS PSYCHOTIC-LIKE AND DISORGANIZED SYMPTOMS IN DAILY LIFE: AN EXPERIENCE SAMPLING STUDY
Publicado: (2020)

T5. STRESS SENSITIZATION AS THE UNDERLYING MECHANISM LINKING CHILDHOOD TRAUMA AND PSYCHOTIC-LIKE SYMPTOMS IN NONCLINICAL YOUNG ADULTS
por: Torrecilla, Pilar, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

T6. ASSOCIATION BETWEEN THE USE OF AN ANTIPSYCHOTIC DRUG AND CHANGES IN LIPID PROFILE: A META-ANALYSIS
por: Brierley, Beverley, et al.
Publicado: (2020)

T236. A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS
por: Velligan, Dawn, et al.
Publicado: (2020)

T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

T128. ATTACHMENT REPRESENTATIONS IN CHILDREN AT FAMILIAL HIGH RISK OF SEVERE MENTAL DISORDERS. ASSOCIATIONS WITH PSYCHOPATHOLOGY, LEVEL OF FUNCTIONING, AND PSYCHOTIC EXPERIENCES
por: Gregersen, Maja, et al.
Publicado: (2020)

T158. NO ALTERATION OF PITUTARY VOLUME IN PATIENTS WITH FIRST-EPISODE SCHIZPHRENIA BUT A TREND OF ENLARGEMENT IN NON-PSYCHOTIC FIRST-DEGREE RELATIVES
por: Chu, Min-yi, et al.
Publicado: (2020)

T185. OLIGOPEPTIDASES IN SCHIZOPHRENIA
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ec7568bg5sj88k563ubqet0q32